The function of p27 KIP1 during tumor development
1Department of Clinical Lab Science, Dongseo University, Busan 617-716, Korea.
Abstract:
Timely cell cycle regulation is conducted by sequential activation of a family of serine-threonine kinases called cycle dependent kinases (CDKs). Tight CDK regulation involves cyclin dependent kinase inhibitors (CKIs) which ensure the correct timing of CDK activation in different phases of the cell cycle. One CKI of importance is p27(KIP1). The regulation and cellular localization of p27(KIP1) can result in biologically contradicting roles when found in the nucleus or cytoplasm of both normal and tumor cells. The p27(KIP1) protein is mainly regulated by proteasomal degradation and its downregulation is often correlated with poor prognosis in several types of human cancers. The protein can also be functionally inactivated by cytoplasmic localization or by phosphorylation. The p27(KIP1) protein is an unconventional tumor suppressor because mutation of its gene is extremely rare in tumors, implying the normal function of the protein is deranged during tumor development. While the tumor suppressor function is mediated by p27(KIP1)s inhibitory interactions with the cyclin/CDK complexes, its oncogenic function is cyclin/CDK independent, and in many cases correlates with cytoplasmic localization. Here we review the basic features and novel aspects of the p27(KIP1) protein, which displays genetically separable tumor suppressing and oncogenic functions.
Insights
The cell cycle regulator p27(KIP1) acts as both a tumor suppressor and oncogene, depending on its location and regulation. Its dual role, independent of gene mutation, offers insights into cancer development.
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Background:
- Cell cycle progression relies on cyclin-dependent kinases (CDKs) tightly regulated by cyclin-dependent kinase inhibitors (CKIs).
- p27(KIP1) is a crucial CKI whose cellular localization and regulation impact its function.
- Dysregulation of p27(KIP1) is linked to various human cancers.
Purpose of the Study:
- To review the fundamental characteristics and novel aspects of p27(KIP1).
- To explore the distinct tumor-suppressing and oncogenic functions of p27(KIP1).
- To understand the implications of p27(KIP1) dysregulation in cancer biology.
Main Methods:
- Review of existing literature on p27(KIP1) regulation, localization, and function.
- Analysis of studies investigating the dual roles of p27(KIP1) in normal and tumor cells.
- Examination of the mechanisms underlying p27(KIP1) inactivation and its correlation with cancer prognosis.
Main Results:
- p27(KIP1) exhibits context-dependent roles, functioning as a tumor suppressor in the nucleus and potentially as an oncogene in the cytoplasm.
- Its tumor suppressor activity involves inhibition of cyclin/CDK complexes, while its oncogenic function is independent of these interactions.
- Downregulation and cytoplasmic mislocalization of p27(KIP1) are associated with poor prognosis in several cancers.
Conclusions:
- p27(KIP1) is an unconventional tumor suppressor, with its oncogenic potential arising from altered regulation and localization rather than gene mutation.
- Understanding the separable tumor-suppressing and oncogenic functions of p27(KIP1) is critical for cancer research and therapeutic strategies.
- Further investigation into p27(KIP1) regulation and localization may reveal new targets for cancer treatment.
Related Concept Videos
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Inhibition of Cdk Activity
Abnormal Proliferation
Negative Regulator Molecules
mTOR Signaling and Cancer Progression
The mTOR pathway or the...


